Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugate for ADC
DBM-GGFG-NH-O-CO-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, functioning primarily as a topoisomerase I inhibitor. It is utilized in the synthesis of ADC molecules to effectively target and deliver cytotoxic agents to specific cell populations, enhancing therapeutic efficacy while minimizing systemic toxicity. This compound plays a vital role in cancer research by facilitating the development of targeted therapies. -
Drug-Linker Conjugates for ADC
Cys-MC-VC-PAB-MMAE is a cleavable drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). The linker comprises Cys-MC-VC-PAB, facilitating selective release of the potent tubulin inhibitor Monomethyl auristatin E (MMAE) upon internalization. This compound enhances the efficacy of ADCs by delivering chemotherapeutic payloads directly to target cells, thereby improving therapeutic outcomes in cancer research applications. -
Drug-linker Conjugates For ADC
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-(5-Cl)-Exatecan is a specialized drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound combines a linker with Exatecan, a potent topoisomerase I inhibitor, to facilitate targeted delivery of the drug to cancer cells. It demonstrates significant cytotoxic activity by promoting DNA damage and cell apoptosis, making it a valuable tool in cancer research and therapeutic development. Applications include studies focused on ADC efficacy and specificity in treating various malignancies. -
Drug-Linker Conjugate for ADC
Mal-C6-α-Amanitin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features α-Amanitin, a potent inhibitor of RNA polymerase II, linked through the Mal-C6 spacer. Its primary biological activity includes significant antitumor effects, making it a valuable tool for targeted cancer therapies and research in oncology. -
Drug-Linker Conjugate for ADC
Mc-Phe-Lys-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the stable attachment of cytotoxic agents to antibodies, enhancing targeted delivery and minimizing systemic toxicity. Its use in ADC synthesis supports the development of novel therapeutic strategies in cancer research and treatment. -
Drug-Linker Conjugates for ADC
Mal-va-mac-SN38 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, incorporating the potent cytotoxin SN-38 linked via a stable linker. This compound exhibits rapid and covalent binding to endogenous albumin in vivo, leading to the formation of HSA-va-mac-SN38. Demonstrating remarkable stability in human plasma, Mal-va-mac-SN38 has shown significant anti-tumor and anti-metastasis effects, providing a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
PB089 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a polyethylene glycol (PEG) unit along with a cleavable linker, which facilitates the delivery of the cytotoxic agent Exatecan to target cells. This compound is valuable for enhancing the therapeutic index of ADCs by improving selectivity and minimizing off-target effects in cancer research. -
Drug-Linker Conjugates for ADC
MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a peptide-based ADC linker with Exatecan, a potent DNA topoisomerase I inhibitor, enhancing targeted therapeutic efficacy. This conjugate is suitable for research into cancer treatment mechanisms and the development of ADCs, providing insights into tumor cell response to topoisomerase I inhibition. -
Drug-linker Conjugate for ADC
Val-Cit-PABC-DOX is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises Doxorubicin, a potent inhibitor of DNA topoisomerase I and II, linked through the Val-Cit-PABC linker technology. This compound facilitates targeted delivery of Doxorubicin, enhancing its therapeutic efficacy while minimizing off-target effects, making it a valuable tool for cancer research and development. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VA-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It features a potent tubulin inhibitor, MMAE, linked via a cleavable moiety, DBCO-PEG4-VA-PABC, facilitating targeted delivery to cancer cells. This conjugate is suitable for the synthesis of ADCs, demonstrating potential application in targeted cancer therapies by enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugates for ADC
(1R)-Deruxtecan is a potent drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing systemic toxicity. It is valuable in cancer research and development, particularly for optimizing ADC formulations and assessing their pharmacological profiles. -
Drug-Linker Conjugate for ADC
Fmoc-NMe-Val-Val-Dil-Dap-OH serves as an essential intermediate in the synthesis of drug-linker conjugates, specifically MC-MMAF. This compound is pivotal for the development of antibody-drug conjugates (ADCs), facilitating targeted drug delivery in therapeutic applications. Its unique structure supports the formation of stable linkages essential for effective ADC formation and enhances the specificity and efficacy of cancer therapies. -
Drug-Linker Conjugates For ADC
N3-PEG3-VC-PAB-MMAF is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a potent tubulin inhibitor, MMAF, linked via the N3-PEG3-VC-PAB moiety. This compound serves as a click chemistry reagent, facilitating the copper-catalyzed azide-alkyne cycloaddition (CuAAc) reaction with alkyne-containing molecules. Additionally, it can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN-functionalized compounds, making it valuable for targeted drug delivery and therapeutic development in cancer research. -
Drug-Linker Conjugates for ADC
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a protease-cleavable MC-GGFG linker, allowing for targeted delivery and release of the cytotoxic agent camptothecin upon cleavage in the tumor microenvironment. Its structural design enhances therapeutic efficacy while minimizing systemic toxicity, making it a valuable tool for cancer research and development of targeted cancer therapies. -
Drug-Linker Conjugates for ADC
SC-VC-PAB-DM1 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs), employing DM1 (Mertansine), a potent tubulin inhibitor. This conjugate exhibits significant antitumor activity through targeted delivery, facilitating the precise release of the cytotoxic agent in malignant tissues. SC-VC-PAB-DM1 is suitable for research applications focused on cancer therapeutics and the development of effective ADCs. -
Drug-Linker Conjugates for ADC
Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan is a specialized drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features an Exatecan cytotoxin, which targets and inhibits DNA topoisomerase I, leading to apoptotic cell death in cancer cells. It is ideal for research in targeted cancer therapies, enhancing the effectiveness of ADCs while minimizing systemic toxicity. -
Drug-Linker Conjugates for ADC
Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound comprises the cytotoxic agent Hydrotecan and a peptide linker featuring L-Ala, L-Val, and L-Gln residues. It is utilized in research focused on targeted cancer therapies, facilitating the selective delivery of cytotoxic agents to tumor cells while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan serves as a drug-linker conjugate utilized in antibody-drug conjugate (ADC) applications. This compound demonstrates significant potential in targeted cancer therapy, allowing for the selective delivery of cytotoxic agents to tumoral cells. Its design facilitates efficient drug release upon internalization, enhancing therapeutic efficacy while minimizing systemic exposure. Researchers can explore its utility in developing novel ADC formulations for improved treatment strategies. -
Drug-Linker Conjugate for ADC
Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker (Aminocaproyl-Val-Cit-PABC) linked to Exatecan, a potent topoisomerase I inhibitor. It is suitable for synthesizing ADC molecules, facilitating targeted cancer therapies by delivering cytotoxic agents directly to cancer cells while minimizing effects on normal tissues. -
Drug-Linker Conjugates for ADC
Mc-Pro-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound comprises Monomethyl auristatin E (MMAE) conjugated through a proprietary linker, enabling targeted delivery of cytotoxic agents to tumor cells. Mc-Pro-PAB-MMAE is suitable for the synthesis of ADCs, allowing researchers to explore novel therapeutic strategies in cancer treatment. -
Drug-Linker Conjugates for ADC
VcMMAE-Eribulin is a targeted drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent microtubule inhibitors MMAE and Eribulin. This compound facilitates the selective delivery of cytotoxic agents to cancer cells, enhancing the therapeutic efficacy while minimizing off-target effects. VcMMAE-Eribulin is essential for synthesizing ADCs aimed at targeted cancer treatments, making it a valuable tool in oncological research. -
Drug-Linker Conjugates for ADC
Val-Ala-PABC-Exatecan trifluoroacetate is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises a cleavable Val-Ala-PABC linker and Exatecan, a potent topoisomerase I inhibitor. This reagent enables the synthesis of ADC molecules by facilitating targeted delivery and controlled release of the cytotoxic agent, making it suitable for advancing cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It integrates Exatecan, a potent inhibitor of DNA Topoisomerase I, with an IC50 value of 2.2 μM. This conjugate enables targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. It is suitable for research involving ADC development and optimization in cancer therapeutics. -
Drug-Linker Conjugate for ADC
2-MSP-5-HA-VA-PAB-Exatecan is a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound incorporates Exatecan, a potent topoisomerase I inhibitor, linked via a stable spacer. It is utilized in the synthesis of ADCs, enabling targeted delivery of cytotoxic agents to cancer cells, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugates For ADC
Aminobenzenesulfonic auristatin E is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound exhibits potent antitumor activity through its mechanism as a cytotoxic tubulin modifier, utilizing Auristatin E linked via the aminobenzenesulfonic linker. It is valuable for research focused on enhancing targeted cancer therapies by improving the efficacy and selectivity of therapeutic agents. -
Drug-Linker Conjugate for ADC
mp-dLAE-PABC-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound incorporates Monomethyl auristatin E, a potent tubulin inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in target cells. It is particularly valuable in cancer research and therapeutic applications, enabling the targeted delivery of cytotoxic agents to enhance treatment efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
LNK2-S is a drug-linker conjugate designed for the synthesis of antibody-drug conjugates (ADCs). This compound features the toxin molecule Exatecan, enabling targeted delivery of cytotoxic agents to cancer cells. LNK2-S is suitable for research applications focused on ADC development, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
LP-6 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. It features an Eg5 inhibitor that effectively targets mitotic kinesins, providing potent anti-cancer activity. This compound is crucial for developing ADCs aimed at precise and targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
Lys-Nε-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the potent tubulin inhibitor DM4 with the Lys-Nε-SPDB linker to facilitate targeted delivery and enhanced therapeutic efficacy. Lys-Nε-SPDB-DM4 is suitable for research focused on cancer therapeutics, particularly in studies investigating the mechanisms of action and optimization of ADCs. -
Drug-Linker Conjugates for ADC
MC-VC-PAB-Daptomycin is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It comprises Daptomycin, a lipopeptide antibiotic known for its potent antibacterial activity, linked through a specialized polymeric bridge. This conjugate facilitates targeted delivery of therapeutic agents, enhancing the efficacy of ADCs in treating various cancers and bacterial infections. Its unique structure allows for selective action while minimizing off-target effects, making it a valuable tool in drug development and research applications. -
Drug-Linker Conjugate for ADC
Val-Ala-PAB-SN38 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, combining the Val-Ala-PAB linker with SN38, the active metabolite of the Topoisomerase I inhibitor Irinotecan. This compound is engineered to facilitate targeted delivery of chemotherapy, enhancing the efficacy and specificity of cancer treatment. It is useful for research focused on ADC development and the investigation of Topoisomerase I inhibition in cancer therapy. -
Drug-Linker Conjugates for ADCs
Boc-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a Boc-Val-Cit-PAB linker connected to the microtubule inhibitor MMAE, facilitating targeted delivery of cytotoxic agents to cancer cells. Boc-Val-Cit-PAB-MMAE is suitable for the synthesis of ADCs, enhancing therapeutic efficacy while minimizing off-target effects in cancer research. -
Drug-Linker Conjugates for ADC
DL-01 is a drug-linker conjugate specifically designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing systemic toxicity. DL-01 is essential for research applications focusing on ADC development and optimization in cancer therapy. -
Drug-Linker Conjugate for ADC
Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This reagent facilitates targeted delivery of the potent antitumor antibiotic Duocarmycin SA through its unique linker structure, Mal-PEG4-VC-PAB-DMEA-Seco. Its primary mechanism involves the selective release of the cytotoxic agent upon cellular internalization, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is suitable for cancer research focused on developing and optimizing ADCs for improved clinical outcomes. -
Drug-Linker Conjugate for ADC
Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, combining a cleavable linker (Aminocaproyl-Val-Cit-PABC) with Exatecan, a potent topoisomerase I inhibitor. This compound facilitates targeted cytotoxic activity, which is crucial for the development of effective ADCs. It is suitable for research aimed at enhancing the efficacy and specificity of cancer therapies through ADC synthesis. -
Drug-linker Conjugate for ADC
DBCO-PEG3-Glu-VC-PABC-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features the tubulin inhibitor MMAF linked through a cathepsin cleavable DBCO-PEG3-Glu-VC-PABC moiety, facilitating targeted delivery of the cytotoxic agent. This compound is valuable for research applications focusing on the development of ADCs, enabling studies on efficacy, mechanism of action, and therapeutic potential in cancer treatment. -
Drug-Linker Conjugates for ADC
AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features the natural bis-intercalator SW-163D linked through the AcLysValCitPABC-DMAE moiety, facilitating targeted delivery of cytotoxic agents. It is instrumental in enhancing the efficacy of ADCs by improving specificity and reducing off-target effects in cancer research applications. -
Drug-Linker Conjugate for ADC
MC-Val-Cit-PAB-Ispinesib is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a cleavable linker combined with the Eg5 inhibitor, ispinesib. This compound enables the targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. Its unique structure facilitates the precise synthesis of ADCs, making it a valuable tool for cancer research and development.
